Filing Flows › Medpace Holdings (MEDP) › Q2 2026 › vs Q2 2025
Medpace Holdings (MEDP) Q2 2026 vs Q2 2025 (year over year)
Medpace Holdings's revenue rose $104M (+17%) from $603M in Q2 2025 to $707M in Q2 2026. The biggest changes: Other +$71.2M (+48%); Cardiology +$21.7M (+36%); Metabolic +$20.8M (+11%). Operating margin 20.8% against 20.9% (-0.2 pts).
Medpace Holdings, Q2 2026: revenue $707M (+17% year over year), operating margin 20.8%, net earnings $121M, operating cash flow $162M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 20.8% | 20.9% | -0.2 pts |
| Net margin | 17.2% | 15.0% | +2.2 pts |
| Free cash flow margin | 19.5% | 23.6% | -4.1 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Other | $219M | $148M | $71.2M | +48% |
| Metabolic | $209M | $189M | $20.8M | +11% |
| Oncology | $98.3M | $118M | −$19.8M | -17% |
| Cardiology | $82.9M | $61.1M | $21.7M | +36% |
| Central Nervous System | $60.0M | $58.6M | $1.4M | +2% |
| AVAI | $37.8M | $29.1M | $8.7M | +30% |
| Revenue | $707M | $603M | $104M | +17% |
| Other income, net | $4.8M | −$1.8M | $6.6M | — |
| Operating profit | $147M | $126M | $20.5M | +16% |
| Costs & expenses | $561M | $477M | $83.5M | +18% |
| Pre-tax earnings | $152M | $125M | $27.1M | +22% |
| SG&A | $48.1M | $46.7M | $1.4M | +3% |
| Other operating costs | $512M | $430M | $82.1M | +19% |
| Net earnings | $121M | $90.3M | $31.1M | +34% |
| Income tax | $30.3M | $34.3M | −$4.0M | -12% |
| Depreciation & amortization | $6.7M | $7.0M | −$304K | -4% |
| Share-based compensation | $4.3M | $6.0M | −$1.6M | -27% |
| Working capital & other | $29.6M | $45.3M | −$15.7M | -35% |
| Operating cash flow | $162M | $149M | $13.5M | +9% |
| Free cash flow (OCF − capex) | $138M | $142M | −$4.3M | -3% |
| Capital expenditures | $23.9M | $6.1M | $17.8M | +291% |
Questions
How much did Medpace Holdings's revenue grow year over year in Q2 2026?
Medpace Holdings's revenue rose $104M (+17%) from $603M in Q2 2025 to $707M in Q2 2026.
What drove Medpace Holdings's revenue change in Q2 2026?
Other +$71.2M (+48%); Cardiology +$21.7M (+36%); Metabolic +$20.8M (+11%).